RNAC Cartesian Therapeutics, Inc.
$6.46▲ +2.87%
Healthcare
Other
Volume 118.8K
Avg Volume (10D) 134.8K
Key Metrics & Fundamentals
Market Cap
$195.45M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.60 - 11.00
% vs 50 MA
-18.59%
% vs 200 MA
-15.68%
RSI-14
39.9
MACD Histogram
+0.0500
Beta (1Y vs SPY)
1.49
Free Cash Flow
-$21.35M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$27.15M
COGS
–
Operating Exp
$29.16M
Operating Income
-$29.16M
EBIT
-$29.16M
Pretax Income
$15.77M
Net Income
$15.77M
EPS (Diluted)
0.46
Price & Volume History
Loading chart…
Recent News
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire · Oct 2, 2026 7:00 AM ET
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
GlobeNewswire · Sep 29, 2026 7:30 AM ET
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire · Sep 8, 2026 7:00 AM ET
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 7:00 AM ET
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire · Aug 7, 2026 7:00 AM ET
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See RNAC's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.